News

Publishing your work in "Precision Nanomedicine"

Dear COSTers,

as a follow up of Prof. Balogh's seminar, in this page you can find all information about the possibility of publishing your work in Precision Medicine. The same info can be also downloaded in pdf from this page.

Why publish in Precision Nanomedicine?

Not every scientist can afford to publish in prestigious but expensive commercial journals while avoiding predatory publishers. For them, there is Precision Nanomedicine, https://precisionnanomedicine.com/ an upcoming international journal

Precision Nanomedicine (PRNANO) is a free, open access, peer-reviewed journal that promotes all practical, rational, and progressive aspects of nanomedicine and medicine from basic science through commercialization.

It is the official journal of the European Foundation for Clinical Nanomedicine (www.CLINAM.org) and endorsed by the International Society for Nanomedicine (ISNM, Basel), by the European Society for Clinical Nanomedicine (ESNAM), and by the British Society of Nanomedicine (https://www.britishsocietynanomedicine.org/bsnm-journal/).

What is the difference to other journals?

  • We are renowned scientists who own a nonprofit publisher (https://andoverhouse.org/). Our primary goal is to provide a high-quality professional forum with reliable content and cutting-edge science

  • There are neither APC-s nor other fees

  • Authors retain their full ownership of their published material

  • Quality is guaranteed by our Associate Editors (10,000 citations on average), and International

    Editorial Board (9,000 citations), and by the Honorary Board (30,000 citations on average)

    https://precisionnanomedicine.com/editorial-board

  • PRNANO accepts both original and replication studies, including submissions of negative results, as long as they are clearly marked as such and move the field forward

  • We help authors to publish their work. Peer-reviews are not intimidating critiques but suggest ways how to improve the manuscript

  • We publish in realistic times (2-4 weeks). Articles carry a unique DOI, archived for preservation, and available to download for free 24/7

  • In addition to posting on our homepage, we actively publicize your paper on social media via a 1300-member mailing list and by posting it to 66 nanomedicine related Linkedin page, potentially reaching 800,000 readers

  • Articles are archived in Portico, indexed, or abstracted in Crossref, DOAJ, and Google. PRNANO’s publisher, Andover House Inc., is a member of COPE (https://publicationethics.org), the Free Journal Network (https://freejournals.org) and SFDORA (https://sfdora.org).

    Note: Precision Nanomedicine tripled the number of its readers in 2019 and quadrupled it in 2020. It presently has 18000 unique readers and growing.

Online workshop on "FDA Guidance: Drug Products Containing Nanomaterial"

Dear COSTers,

It is a pleasure to announce the upcoming Action webinar entitled "FDA Guidance: Drug Products Containing Nanomaterial" proferred by Dr. Anil Patri, an authority in the field.

The webinar will be held on November 2nd at 8:30 am US EST.

Dr. Patri will focus his lecture on overarching guidance that applies to all products containing nanomaterial and the draft guidance specific to drug products and biologics. In the process, he will bring up about factors to consider when one develops a product through pre-clinical testing.

More info, details and registration to the webinar will be available soon.

A short bio of Dr. Patri can be downloaded from this page.

You are invited to attend!

Useful downloads

MEET OUR INDUSTRIAL PARTNERS! TWO UPCOMING WORKSHOPS OF OUR CA17140

Dear COSTers,

it is our pleasure to announce our MEET OUR INDUSTRIAL PARTNERS upcoming virtual workshops.

The agreed dates and schedules for these two online meeting are Tursday 23/9 at 5-6pm CET and Thursday 30/9 at 5-6pm CET.

The industrial partners who kindly agreed to participate in the workshops and their contributions are:


WS on Tursday 23/9 at 5-6pm CET

Phoenix Open Innovation Test Bed for GMP Manufacturing of Nanopharmaceuticals
Dr. Nazende Günday-Türeli, MyBiotec, Germany

Lipid Nanoparticles methods, characteristics and applications in drug delivery
Dr. Paolo Gasco, Nanovector, Italy

Safety-by-design – important cornerstones on the way to the (nano)market
Dr Andreas Falk, BioNanoNet, Austria


WS on Thursday 30/9 at 5-6pm CET

Preclinical toxicity studies at Cellvax
Dr. Mingxing Wei, CellVax, France

Biomedical applications of thick film technology
Dr. Marin Gheorghe, NANOM MEMS, Romania

The REFINE Decision Support System (DSS) for cost- efficient preclinical assessment of nano(bio)materials used in the medical sector
Dr. Lisa Pizzol, GreenDecision, Italy


You can also save the preliminary event flyer available for download on this page.

More info will be posted soon. Stay tuned!

VIRTUAL NETWORKING MOBILITY GRANTS - CALL NOW OPEN

Dear COSTers,

the CA17140  Cancer nanomedicine - from the bench to the bedside call for expression of interest for VIRTUAL NETWORKING MOBILITY GRANTS is now open.

ELIGIBILITY CRITERIA

Applicants are CA17140 Action participants with a primary affiliation to an institution located in a COST Full or Cooperating Member country or MC Observers from a COST Near Neighbour Country.

Applicants shall provide information about the aim of the VM Grant and how its outcomes will generate benefits to the Action CA17140, actively contribute to the activities and overall objectives of the Action and submit a report at the end, to be approved by the VNS manager on behalf of the MC.

EVALUATION AND SELECTION OF APPLICANTS

The evaluation of applications is performed by the CA17140 Action’s Virtual Networking Support (VNS) Manager with the support of the Core Group, if necessary. The selection of successful grantees shall be based on contributions to the overall objectives of the Action and the implementation of the COST Excellence and Inclusiveness Policy as well as the approved strategy on virtual networking for the Action CA17140, if available.

The applications shall be submitted in e-COST and include required information detailed in the Vademecum, section 10.2.2.

IMPLEMENTATION OF ACTIVITIES

The requirements on activities expected to be performed by the successful applicant are listed in section 10.2.3 of the Vademecum.

The successful applicants shall implement the workplan approved in their application within the time frame also there defined and within CA 17140 Grant Period lasting until October 31, 2021.

The grantee will have the obligation to actively contribute to the activities of the relevant Action WG.

The grantee has 30 calendar days from the completion of the Virtual Mobility Grant to submit a report to the Action Chair/ the VNS Manager and to the Science Officer of the Action.

TIME SCHEDULE:

Deadline for applications submission: open collection.

With the provision that the submission and grant implementation will be within the Grant Period lasting until October 31, 2021, taking into account application evaluation processing time – up to 7 days.

FINANCIAL SUPPORT:

A maximum of 6 Virtual Mobility Grants will be awarded. Each Virtual Mobility Grant cannot exceed EUR 1500.

The user guide is available for download from this page.

We llok forward to your submissions!

Useful downloads
European Cooperation in Science and Technology (COST) logo
Funded by the European Union